A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alectinib (Primary) ; Entrectinib (Primary) ; Durvalumab
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Sponsors Roche

Most Recent Events

26 Nov 2024 Planned End Date changed from 14 Apr 2035 to 1 Sep 2033.
26 Nov 2024 Planned primary completion date changed from 17 Jun 2029 to 21 Aug 2032.
15 Nov 2023 Pralsetinib drug has been removed from the study. Treatment arms changed from 6 to 4.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight